How much does Sartolizumab cost?

Sacituzumab govitecan (Sacituzumab govitecan) is a drug for the treatment of breast cancer and urothelial cancer. It is a humanized monoclonal antibody drug that combines the characteristics of antibodies and cytotoxic small molecule drugs and can selectively target cancer cells. The development of this drug originated from research on the Trop-2 receptor overexpressed on the surface of breast cancer cells. Trop-2 receptor is a tumor-associated antigen that is highly expressed in a variety of malignant tumors, including breast cancer, bladder cancer, etc.

Gosatuzumab binds to the Trop-2 receptor, guiding it to breast cancer cells and releasing the prodrug form of cytotoxic SN-38. SN-38 is a potent cisplatin derivative with strong cytotoxic effects. Once Todavir enters breast cancer cells, SN-38 will be released, inhibiting DNA synthesis and cell reproduction, thereby destroying the viability of cancer cells. Sartolizumab has shown anti-tumor activity in some clinical trials. It is used to treat patients with refractory metastatic triple-negative breast cancer and urothelial cancer who have received multiple chemotherapy regimens but whose disease has progressed.

Gosatuzumab, a patent-pending drug, has been launched in China under the trade name Tudavi, but it has not yet been covered by medical insurance. Its price is approximately RMB 10,000 per bottle of 180 mg, which is quite expensive. At the same time, the drug is also sold in overseas markets, such as Europe, the United States and Singapore, and the price fluctuates between 10,000 and more than 30,000 yuan due to exchange rates. However, there is no significant difference in the ingredients of gosatuzumab sold domestically and abroad. As of now, no generic version of gosatuzumab is available on the market.